Premium
Extended high cut‐off haemodialysis for myeloma cast nephropathy in A uckland, 2008–2012
Author(s) -
Tan Jasmine,
LamPoTang Michael,
Hutchison Colin A,
Zoysa Janak R
Publication year - 2014
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/nep.12267
Subject(s) - medicine , multiple myeloma , dialysis , nephropathy , renal biopsy , chemotherapy , surgery , hemodialysis , urology , biopsy , endocrinology , diabetes mellitus
Myeloma cast nephropathy contributes to high morbidity and early mortality associated with the development of end‐stage renal disease. Treatment with extended high cut‐off haemodialysis coupled with novel anti‐myeloma therapies enables significant reduction of serum‐free light chains and has been shown to improve renal outcomes. In this case series, medical records of 6 patients who received high cut‐off haemodialysis for biopsy‐proven cast nephropathy were retrospectively reviewed. Patients received a total of 344 hours of high cut‐off haemodialysis and concurrent chemotherapy. Only 50% became dialysis independent following treatment. One patient who achieved sustained remission remained dialysis dependent. The added benefit of high cut‐off haemodialysis in the light of novel anti‐myeloma therapies requires further evaluation.